azathioprine

Prednisone, azathioprine, and mycophenolate carried higher risks of serious infections at 6 months than methotrexate or cyclosporine, the authors said.

Azathioprine (AZA) (Immuran, GlaxoSmithKline, Middlesex, UK) was started at a dose of 2-2.5 mg/kg/d at the time of diagnosis or as the maintenance therapy during evaluation for a dose reduction of steroids at 4, 8, or 12 weeks.

The label update was based on data from a Roche-supported study by the French Vasculitis Study Group showing that treatment with the rituximab regimen resulted in fewer major relapses by month 28 compared to treatment with azathioprine. The observed safety profile was consistent with that previously observed in this patient population.

Following pulse therapy, 64 mg oral prednisolone and 150 mg (50 mg 3 times daily) azathioprine were co-administered.

Azathioprine (AZA) still corresponds to the mainstay maintenance therapy in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (1, 2).

At symptom onset, she had received infliximab and azathioprine for >5 years and reported eating undercooked meat; she had not traveled abroad.

Azathioprine is an immunosuppressant used in the treatment of various autoimmune conditions, including myasthenia gravis.

Thiopurines, azathioprine (AZA), and 6-mercaptopurine (6MP) have been considered the reference maintenance treatment for patients with steroid-dependent and steroid-refractory moderate-to-severe UC for many years and are recommended as the first line immunosuppressive therapy by major guidelines [1, 5].

Immunomodulators including azathioprine, calcineurin inhibitors, and cyclosporine have been tried with mixed success [8, 16, 17].

1 mg/kg/day oral corticosteroid, 25 mg/day azathioprine, warfarin tailored to international normalized ratio target, 3 tablets/day acetazolamide and 1 tablet/day potassium were started for the patient.